Voriconazole

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Voriconazole is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

Abdominal MassAbdominal Mass

metoprololmetoprolol

Hepatic AbscessHepatic Abscess

Inguinal HerniaInguinal Hernia

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
    • Invasive aspergillosis
    • Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
    • Esophageal candidiasis
    • Candidemia in non-neutropenic patients and other deep tissue Candida infections

NON-FDA APPROVED USES

  • Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
  • Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
    • Invasive aspergillosis
    • Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
    • Esophageal candidiasis
    • Candidemia in non-neutropenic patients and other deep tissue Candida infections

NON-FDA APPROVED USES

  • Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
  • Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved